- Home
- PRA vs ZLAB Comparison
PRA vs ZLAB Comparison
Compare PRA & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRA
- ZLAB
- Stock Information
- Founded
- PRA 1976
- ZLAB 2013
- Country
- PRA United States
- ZLAB China
- Employees
- PRA N/A
- ZLAB N/A
- Industry
- PRA Property-Casualty Insurers
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- PRA Finance
- ZLAB Health Care
- Exchange
- PRA Nasdaq
- ZLAB Nasdaq
- Market Cap
- PRA 1.2B
- ZLAB 3.6B
- IPO Year
- PRA N/A
- ZLAB 2017
- Fundamental
- Price
- PRA $23.63
- ZLAB $36.40
- Analyst Decision
- PRA Hold
- ZLAB Buy
- Analyst Count
- PRA 4
- ZLAB 5
- Target Price
- PRA $21.00
- ZLAB $54.28
- AVG Volume (30 Days)
- PRA 550.6K
- ZLAB 886.5K
- Earning Date
- PRA 08-07-2025
- ZLAB 08-05-2025
- Dividend Yield
- PRA N/A
- ZLAB N/A
- EPS Growth
- PRA N/A
- ZLAB N/A
- EPS
- PRA 0.83
- ZLAB N/A
- Revenue
- PRA $1,140,267,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- PRA N/A
- ZLAB $44.07
- Revenue Next Year
- PRA $1.25
- ZLAB $49.13
- P/E Ratio
- PRA $28.57
- ZLAB N/A
- Revenue Growth
- PRA N/A
- ZLAB 43.72
- 52 Week Low
- PRA $10.76
- ZLAB $16.01
- 52 Week High
- PRA $23.73
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- PRA 76.83
- ZLAB 52.67
- Support Level
- PRA $22.79
- ZLAB $34.79
- Resistance Level
- PRA $22.88
- ZLAB $36.73
- Average True Range (ATR)
- PRA 0.16
- ZLAB 1.23
- MACD
- PRA 0.04
- ZLAB -0.46
- Stochastic Oscillator
- PRA 133.82
- ZLAB 25.91
About PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.